Therapeutic and research frontiers in fibromyalgia: integrating pathophysiology with innovative drug repurposing
Sheer A. Joodi, Dalia A. Nawwar, Nora O. Abdel Rasheed, Weam W. Ibrahim, Helmy M. Sayed · 2026
Read Therapeutic and research frontiers in fibromyalgia: integrating pathophysiology with innovative drug repurposing by Sheer A. Joodi, Dalia A. Nawwar, Nora O. Abdel Rasheed, Weam W. Ibrahim, Helmy M. Sayed (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13525016.txt.
Description
Sheer A. Joodi and others review, in a 2026 paper, research and treatment frontiers in fibromyalgia, a chronic syndrome of widespread pain, fatigue, broken sleep, and trouble thinking. Few drugs are cleared for it, and they mainly ease symptoms, often not enough or with harsh side effects. The review joins disease mechanisms with new uses for old drugs.
Topics covered include altered neurochemistry, central sensitization where pain signaling grows louder, neuroinflammation, oxidative stress, mitochondrial problems, gut microbe upset, and autoimmunity. Drug classes reused this way range from antidepressants and antiepileptics to cannabinoids, melatonin agonists, and antidiabetic agents, most still in lab or early human testing. The authors urge work on several fronts: stronger descending pain inhibition, a calmer specific inflammasome, and repair of oxidative and mitochondrial dysfunction.
Catalog record
| CREATOR | Sheer A. Joodi, Dalia A. Nawwar, Nora O. Abdel Rasheed, Weam W. Ibrahim, Helmy M. Sayed |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 61181 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |